Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double‐blind, active‐comparator, 24‐week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal antibody targeting proprotein convertase subti...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Jennifer G., Colhoun, Helen M., Bays, Harold E., Jones, Peter H., Du, Yunling, Hanotin, Corinne, Donahue, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2014
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282386/
https://www.ncbi.nlm.nih.gov/pubmed/25269777
http://dx.doi.org/10.1002/clc.22327

Ejemplares similares

Ejemplares similares